U.S. Food and Drug Administration

Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement with Vivalis to Explore Production Of MVA85A TB Vacci

 OXFORD, England, ROCKVILLE, Md., & NANTES, France–(BUSINESS WIRE)–The Oxford-Emergent Tuberculosis Consortium Ltd., a joint venture between the University of Oxford and Emergent BioSolutions Inc.

Submitted by admin on Thu, 07/23/2009 - 13:42. categories [ ]

Emergent BioSolutions Buys Rival Vaccine for $2 Million

 Lansing-based Emergent BioSolutions picked up its U.S. rival’s anthrax vaccination technology for $2 million, strengthening the company’s ability to make a second anthrax vaccination.

According to excerpts from the article:

In Lansing, the acquisition of VaxGen Inc.’s vaccine could add a second product line at a new plant.

Submitted by admin on Thu, 07/23/2009 - 13:40. categories [ ]

Emergent BioSolutions hands out bonuses

 Bonus may be a bad word right now — but not for a biotech that is actually making money.

Alongside minimal pay raises, Emergent BioSolutions Inc. execs received bonuses in 2008 that increased anywhere from 5 percent to 43 percent from their 2007 bonuses. Fuad El-Hibri, chief executive of

Submitted by admin on Thu, 07/23/2009 - 13:39. categories [ ]